Table 1.
Select characteristics of HIV positive cases and controls from the Multicenter AIDS Cohort Study
| Serum marker association study | Genetic association study | |||
|---|---|---|---|---|
|
| ||||
| AIDS-NHL cases | HIV+ controls | AIDS-NHL cases | HIV+ controls | |
|
| ||||
| N | 179 | 179 | 183 | 533 |
| Baseline visit year, N (%) | ||||
| 1984–1985 | 158 (88) | 160 (89) | 163 (89) | 479 (90) |
| 1987–1991 | 21 (12) | 19 (11) | 20 (11) | 54 (10) |
| Reference year, N (%)a | ||||
| 1984–1995 | 155 (86) | 155 (86) | 155 (85) | 450 (84) |
| 1996–2001 | 23 (13) | 24 (13) | 22 (12) | 67 (13) |
| 2002–2006 | 1 (1) | 0 | 6 (3) | 6 (3) |
| MACS site, N (%) | ||||
| Baltimore | 44 (25) | 37 (21) | 45 (25) | 119 (22) |
| Chicago | 42 (23) | 33 (18) | 44 (24) | 130 (25) |
| Pittsburgh | 22 (12) | 39 (22) | 22 (12) | 86 (16) |
| Los Angeles | 71 (40) | 70 (39) | 72 (39) | 198 (37) |
| Age, median years (range)a | 41 (24–60) | 39 (24–60) | 41 (24–60) | 40 (24–70) |
| Race/Ethnicity, N (%) | ||||
| White, non-Hispanic | 149 (83) | 156 (87) | 153 (84) | 483 (90) |
| White, Hispanic | 19 (11) | 8 (4) | 18 (10) | 25 (5) |
| Black, non-Hispanic | 11 (6) | 10 (6) | 12 (6) | 21 (4) |
| Other | 0 | 5 (3) | 0 | 4 (1) |
| HIV RNA at set point, median (range) | 31,133 (400– 960,960) | 14,467 (300– 237,951) | 31,564 (400– 960,960) | 20,698 (300– 672,810) |
| Prior AIDS illness, N (%)b | 94 (53) | 20 (11) | 95 (52) | 220 (41) |
| CD4+ T cell slope, median cells per year (range)c | −74 (−283 to 178) | −44 (−188 to 84) | −67 (−283 to 178) | −60 (−370 to 812) |
| CD4+ T cell count, median cells/mm3 (range)d | 74 (0–707) | 468 (4–1255) | 79 (2–923) | 87 (1–1361) |
| Prior HAART exposure, N (%)b | 8 (4) | 8 (4) | 11 (6) | 46 (9) |
| Tumor Subtype, N (%) | ||||
| Systemic | 121 (68) | – | 125 (68) | – |
| Diffuse large B cell | 60 (50) | – | 65 (52) | – |
| Burkitt lymphoma/BL-like | 21 (17) | – | 21 (17) | – |
| Other subtypes | 6 ( 5) | – | 7 (6) | – |
| Not specified | 34 (28) | – | 32 (26) | – |
| Central nervous system | 58 (32) | – | 58 (32) | – |
| Tumor EBV status, N (%) | ||||
| Not tested | 92 (51) | – | 97 (53) | – |
| Tested | 87 (49) | – | 86 (47) | – |
| Negative | 28 (32) | – | 28 (32) | – |
| Positivee | 59 (68) | – | 58 (67) | – |
At time of AIDS-NHL diagnosis in cases and reference date in controls (determined by matching HIV positive follow-up time to that of the case in the matched set)
At least 30 days prior to AIDS-NHL diagnosis date in cases and reference date in controls
Calculated from all available pre-HAART CD4+ T cell count data
For the serum marker association study cell counts from at 0–1 years prior to AIDS-NHL diagnosis in cases and reference date in controls. For the genetic association study, cell counts from the visit most closely preceding AIDS-NHL diagnosis in cases and reference date in controls
34/59 (58%) of systemic AIDS-NHL tested were EBV positive compared to 25/28 (89%) of PCNSL